3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neoplasms
3
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Neuroendocrine Tumors
2
Neuroectodermal Tumors, Primitive
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoid Tumor
1
Interventions
dactolisib
2
Everolimus
2
surufatinib
1
spartalizumab
1
pasireotide
1
ganitumab
1
fosbretabulin
1
cixutumumab
1
TH 302
1
PM 00104
1
ONC206
1
Fentanyl
1
CLR1404
1
90Y-octreotide, DOTA-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neuroectodermal Tumors, Primitive
×
fosbretabulin
×
Clear all
NCT02132468
2017-12-05
GI-NETorPNET
Mateon Therapeutics
Phase 2
Completed
18 enrolled
10 charts